PMID- 25301674
OWN - NLM
STAT- MEDLINE
DCOM- 20151123
LR  - 20220409
IS  - 1437-4331 (Electronic)
IS  - 1434-6621 (Linking)
VI  - 53
IP  - 4
DP  - 2015 Mar
TI  - Weight loss reduces serum monocyte chemoattractant protein-1 concentrations in 
      association with improvements in renal injury in obese men with metabolic 
      syndrome.
PG  - 623-9
LID - 10.1515/cclm-2014-0468 [doi]
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) is involved in 
      obesity-related renal injury. The aim of the present study was to examine the 
      effects of weight loss on changes in MCP-1 and markers of renal injury, 
      specifically serum cystatin C (S-CysC) and urinary N-acetyl glucosaminidase 
      (UNAG), in obese people. METHODS: In this prospective study, 40 obese men with 
      metabolic syndrome (MetS) participated in a 3-month dietary and exercise 
      intervention. Twenty-eight subjects completed the study with a >/=5% weight loss. 
      Circulating MCP-1, S-CysC and UNAG to creatinine ratio (UNCR) were determined 
      before and after the weight loss program. RESULTS: Obesity-associated components 
      of MetS demonstrated significant improvements after the weight loss program. In 
      addition, at baseline, circulating MCP-1 concentrations were positively 
      correlated with UNCR and S-CysC levels. After weight loss, blood MCP-1 and UNCR 
      levels were significantly decreased, but S-CysC was not affected. Using multiple 
      linear regression analysis, there was a significant relationship between changes 
      in UNCR and MCP-1 after adjusting for other potential confounding factors. 
      CONCLUSIONS: Weight loss may improve renal tubular injury by ameliorating 
      obesity-related inflammation in obese men with MetS.
FAU - Fu, Chia-Po
AU  - Fu CP
FAU - Sheu, Wayne H-H
AU  - Sheu WH
FAU - Lee, I-Te
AU  - Lee IT
FAU - Lee, Wen-Jane
AU  - Lee WJ
FAU - Wang, Jun-Sing
AU  - Wang JS
FAU - Liang, Kae-Woei
AU  - Liang KW
FAU - Lee, Wen-Lieng
AU  - Lee WL
FAU - Lin, Shih-Yi
AU  - Lin SY
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cystatin C)
RN  - EC 3.2.1.50 (alpha-N-acetyl-D-glucosaminidase)
RN  - EC 3.2.1.52 (Acetylglucosaminidase)
SB  - IM
MH  - Acetylglucosaminidase/urine
MH  - Adult
MH  - Chemokine CCL2/*blood
MH  - Cystatin C/blood
MH  - Diet
MH  - Exercise
MH  - Humans
MH  - Kidney/*injuries/*physiopathology
MH  - Male
MH  - Metabolic Syndrome/*complications
MH  - Obesity/blood/*complications/*physiopathology/urine
MH  - *Weight Loss
EDAT- 2014/10/11 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/10/11 06:00
PHST- 2014/05/01 00:00 [received]
PHST- 2014/08/24 00:00 [accepted]
PHST- 2014/10/11 06:00 [entrez]
PHST- 2014/10/11 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - /j/cclm.ahead-of-print/cclm-2014-0468/cclm-2014-0468.xml [pii]
AID - 10.1515/cclm-2014-0468 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 2015 Mar;53(4):623-9. doi: 10.1515/cclm-2014-0468.